Net Sales

6 Months Ended

Jun. 30, 2022

Revenue from Contract with Customer [Abstract]

Net Sales

Note 3. Net Sales

All of the Company’s net sales have been derived from sales of its test kits through its healthcare, business-to-business, international and direct-to-consumer channels. Since receiving the initial EUA in the fourth quarter of 2020, the Company marketed its test products to physicians and licensed healthcare providers through its healthcare channel in the United States. On April 9, 2021, the Company received its first FDA EUA authorization for OTC non-prescription use and expanded its marketing to include domestic testing providers, distributors, businesses within its business-to-business channel, and direct-to-consumer through its partnerships with e-commerce sales and distribution platforms.

The following table sets forth the Company’s net sales by channel:

	Three Months Ended June 30,				Six Months Ended June 30,
	2022		2021		2022		2021
Healthcare	$	1,587	$	235	$	8,458	$	2,622
Business-to-business		10,791		5,324		55,544		6,668
International		1,520		2,166		25,166		2,166
Direct-to-consumer		12,248		4,714		27,452		5,499
Net sales	$	26,146	$	12,439	$	116,620	$	16,955

The following table sets forth the Company’s net sales by geographic area based on the customers’ locations:

	Three Months Ended June 30,				Six Months Ended June 30,
	2022		2021		2022		2021
United States	$	24,626	$	10,273	$	91,454	$	14,789
Canada		605		—		23,924		—
Rest of World		915		2,166		1,242		2,166
Net sales	$	26,146	$	12,439	$	116,620	$	16,955